View of Efficacy and Safety of Tislelizumab Plus Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma

Return to Article Details Efficacy and Safety of Tislelizumab Plus Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma Download Download PDF